timothy sykes logo

Stock News

Amicus Therapeutics Sees Stock Surge Amid BioMarin Acquisition Deal

Bryce TuoheyAvatar
Written by Bryce Tuohey Reviewed by Tim Sykes Fact-checked by Matt Monaco
Updated 12/20/2025, 8:12 am ET 12/20/2025, 8:12 am ET | 5 min 5 min read
Amicus Therapeutics Sees Stock Surge Amid BioMarin Acquisition Deal Thumbnail

Amicus Therapeutics Inc. stocks have been trading up by 30.03% boosted by positive FDA designations and promising results.

Healthcare industry expert:

Analyst sentiment – positive

  1. Market Position & Fundamentals: Amicus Therapeutics (FOLD) occupies a critical space in the rare disease market with strong performance indicators such as an impressive gross margin of 89.8%, due to its specialized product offerings. Despite a revenue increase of 22.8% over three years, profitability remains a challenge with significant negative pretax profit (-35.5%) and total profit margins (-2.35%). The financial strength is reflected in a high current ratio of 3, but concerningly high debt metrics such as total debt to equity of 1.92, and particularly the high price to tangible book value of 187.87, suggesting leverage risk. The company’s revenue per share stands at 1.71, influenced by its expansive R&D investments, but the stock price lacks robust valuation due to a lack of forward P/E levels, indicating speculative positioning in the growth segment without substantial net income return.

  2. Technical Analysis & Trading Strategy: Over the past week, Amicus saw a price surge demonstrated in a significant gap up to $14.16, catalyzed by acquisition news, marking a strong breakout point to watch. The steady upward candle formation, especially the jump from $10.72 to $14.16 signifies bullish investor sentiment and strong upward momentum. With trade volumes peaking around news events, this confirms a positive demand-driven price increase. A recommended bullish trading strategy is to set entering positions around the $14 level, which acts as a new support; potential traders should target a resistance level of $14.50, keeping stop-loss orders just below $13.50 to manage downside risk amid high volatility.

  3. Catalysts & Outlook: The announcement of BioMarin’s acquisition offer at $14.50 per share marks a pivotal moment for Amicus Therapeutics, adding a significant premium over recent trading values. The anticipated strategic benefits from integrating Amicus’ pipeline, primarily Galafold and PomOp’s growing market potential, underscore positive growth prospects within the rare disease sector, pegging potential sales over $1 billion by 2028. The share price’s response with a 30.4% surge demonstrates market validation, though legal scrutiny from fiduciary investigations moderately tempers the outlook. Given these dynamics, Amicus positions favorably within the healthcare sector, likely outperforming Biotechnology benchmarks, with price action bullishly anchored around $14.50, yet potential upward trajectories towards Citi’s $17 target are plausible as the sector consolidates.

Candlestick Chart

Weekly Update Dec 15 – Dec 19, 2025: On Saturday, December 20, 2025 Amicus Therapeutics Inc. stock [NASDAQ: FOLD] is trending up by 30.03%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Amicus Therapeutics has experienced notable financial developments, catalyzing significant market interest. The company’s recent stock movement, buoyed by acquisition news, signals a vital moment in its financial trajectory. Over the past few days, Amicus’ stock rose from around $10.72 to $14.16, marking a 30% increase. This uptick reflects investor confidence driven by the strategic benefits of the acquisition alongside market excitement.

The company’s earnings report underscores key financial metrics. The gross profit stands at $149.59M, driven by operating revenue of $169.06M and a robust gross margin of 89.8%. Despite strong revenue streams, Amicus faces challenges with profit margins, highlighted by a financial report showing a net income of $17.3M against a backdrop of significant operational expenses. The accompanying key ratios reveal a mixed outlook. While the company boasts a high current ratio of 3 and a quick ratio of 1.9, indicating sound short-term liquidity, profitability measures show constraints, with negative margins and unprofitability over the last period.

The financial reports indicate active cash flow management, with a positive change in cash holdings courtesy of strategic operations, including capital expenditures, stock option exercises, and investment sales. However, these are counterbalanced by notable capital outflows tied to debt repayments and investment purchases. With total liabilities amounting to $638.39M, Amicus’ financial strength is somewhat leveraged, necessitating careful management as it transitions post-acquisition.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Bryce Tuohey

Mentor and Trainer at StocksToTrade.com, Lead Mentor at Small Cap Rockets and To The Moon Report
Bryce’s first pattern was buying into strength in breakouts. But he noticed when they didn’t work, he took bigger losses. When the OTC market got hot, Bryce learned to dip buy the inevitable panics. He adapted his breakout strategy and now buys consolidation and trend breaks. His goal is to have better risk/reward and get an entry before multi-day listed breakouts.
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”